Enliven Therapeutics, Inc. (ELVN) FY2025 10-K Annual Report
Enliven Therapeutics, Inc. (ELVN) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 3, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Enliven Therapeutics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Clinical-stage biopharma developing selective small molecule therapeutics targeting validated biology using precision medicine
- • New emphasis on ELVN-001, a selective ATP-competitive BCR-ABL TKI for CML addressing resistance, off-target toxicity, and dosing challenges
Management Discussion & Analysis
- • No revenue generated in FY 2025 or 2024; no expected revenue in foreseeable future
- • Net loss $103.7M in 2025 vs $89.0M in 2024; operating expenses $119.7M vs $104.6M; operating margin negative and worsening
Risk Factors
- • FDA regulatory risk: potential delays or denials if ELVN-001 clinical trial design or data interpretation not accepted, requiring additional clinical studies
- • Geopolitical exposure: clinical development reliant on sites in U.S., Europe and China, subject to global trade tensions and tariffs impact
Enliven Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$104M
▼ -16.5% YoY
ROE
-22.6%
▲ +617bp YoY
Total Assets
$476M
▲ +46.2% YoY
EPS (Diluted)
$-1.83
▲ +3.2% YoY
Operating Cash Flow
-$70M
▲ +3.9% YoY
Source: XBRL data from Enliven Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Enliven Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.